Oncology

Hugo Arasanz: specialist in Medical Oncology, specialized in thoracic oncology and central nervous system tumors, and Doctor of Health Sciences from the Public University of Navarra (2020). He actively participates in clinical trials, some of them as principal investigator, and was coordinator of the FER-FEN-2019-01 trial. In recent years he has participated in different basic/translational research projects with competitive funding, two of them as principal investigator, focused on cancer immunotherapy, biomarker studies, as well as treatment resistance and molecular pathways. He has more than 50 publications in indexed journals, with an h-index of 21.

Imanol Arozarena completed his PhD in Dr. Piero Crespo's laboratory at the University of Cantabria, where he studied the RAS/MAPK pathway. He subsequently, pursued postdoctoral research at the Institute of Cancer Research in London (2006-2009) and at the University of Manchester (2010-2014), where he worked on melanoma skin cancer in the laboratories of Dr. Richard Marais and Dr. Claudia Wellbrock. During this period, Dr. Arozarena focused on the mechanisms of metastatic dissemination and resistance to targeted therapies of tumor cells. After two years working as a professor and Principal Investigator at the University of Huddersfield, he established the Cancer Signaling Unit at Navarrabiomed where he continued his research on melanoma. In the last 8 years he has also developed other research lines focused on brain tumors such as glioblastoma multiforme and metastatic breast cancer. Currently, the Cancer Signaling Unit focuses on investigating the molecular mechanisms and metabolic adaptation that tumor cells develop in response to therapies commonly used in clinical practice such as radiotherapy and immunotherapy.

World's Top 2% Scientists (Stanford University)

Dr. David Escors Murugarren is a Spanish researcher born in Pamplona, Navarre, in 1974. He earned a degree in Biological Sciences from the University of Navarre and completed his doctoral thesis at the Autonomous University of Madrid in 2002. His thesis focused on the structure of the coronavirus of transmissible porcine gastroenteritis and the encapsidation of its genome. After completing his doctorate, he continued his postdoctoral training as a Marie Curie researcher at University College London (UCL), where he collaborated on research about lentiviral vectors and their use in cancer immunotherapy. In 2013, he returned to Spain and joined the Navarrabiomed Research Center, where he leads the immunomodulation group. Dr. Escors specializes in oncological immunotherapy and has published more than one hundred articles, reviews, and book chapters. His research focuses on the development of new immunotherapies for solid tumors, and he has been awarded the V SER Navarra Award (Innovation Category) for his work in research on the

SARS-CoV-22.
(me dice copilot que a ver si no es : SARS-CoV-2)